NCT04844385 2024-02-09
Toripalimab Plus Neoadjuvant Chemotherapy Combined With Chemoradiotherapy for Locally Advanced Unresectable Esophageal Squamous Cell Carcinoma
Sun Yat-sen University
Phase 2 Unknown
Clinical Trials
75 trialsNCT05626569 2024-01-03
Anti-PD-1 Immunotherapy Combined With SBRT for Patients With Oligometastatic ESCC
Sun Yat-sen University
Phase 2 Unknown
NCT05512520 2023-11-18
EC-CRT-003
Sun Yat-sen University
Phase 2 Unknown
NCT06078657 2023-10-12
IBI110 Combined With Sintilimab in Second-line Advanced or Metastatic Esophageal Squamous Cell Carcinoma(ESCC)
The First Affiliated Hospital of Zhengzhou University
Phase 2 Unknown
NCT05990231 2023-09-11
Cadonilimab/Anlotinib in Locally Advanced or Relapsed/Metastatic ESCC Patients After Failure of PD-1 Combined With Platinum-containing Chemotherapy
Second Affiliated Hospital, School of Medicine, Zhejiang University
Phase 2 Unknown
NCT05038813 2023-05-18
Anlotinib Combined With TQB2450 (PD-L1 Inhibitor) in the Treatment of Advanced Esophageal Squamous Cell Carcinoma(ESCC)
The First Affiliated Hospital of Zhengzhou University
Phase 2 Unknown
NCT05163483 2023-03-06
Tucidinostat Plus PD-1 Inhibitor and Bevacizumab for Advanced Esophagus Cancer, AEG, Gastric Cancer
Sun Yat-sen University
Phase 2 Unknown
NCT05650216 2022-12-14
Camrelizumab Combined With Neoadjuvant Concurrent Chemoradiotherapy for Resectable Locally Advanced ESCC（NICE-RT）
Shanghai Chest Hospital
Phase 2 Unknown
NCT05636150 2022-12-05
A Phase II Clinical Study of Fruquintinib Combined With S-1 for Advanced Esophageal Squamous Cell Carcinoma
Peking Union Medical College Hospital
Phase 2 Unknown
NCT05386056 2022-11-28
Pembrolizumab and Photodynamic Therapy in Previously Treated Metastatic Esophageal Squamous Cell Carcinoma
Peking University
Phase 2 Unknown
NCT05596890 2022-11-28
PICCRT
Guangdong Provincial People's Hospital
Phase 2 Unknown
NCT05594914 2022-10-26
AK104 Plus Concurrent Chemoradiation Therapy in Esophageal Squamous Cell Carcinoma
The First Affiliated Hospital of University of South China
Phase 2 Unknown
NCT05552651 2022-09-23
Envafolimab Combined With Chemotherapy in Neoadjuvant Therapy for Resectable Esophageal Squamous Cell Carcinoma
Air Force Military Medical University, China
Phase 2 Unknown
NCT05522894 2022-08-31
AK104 Alone or in Combination With Chemotherapy in the First-line Treatment of ESCC
ChineseAMS
Phase 2 Unknown
NCT04699994 2022-08-17
Prospective Trial to Evaluate the Safety and Efficacy to Treat Esophageal Cancer Using 5-FU, Oxaliplatin, and Docetaxel
Keio University
Phase 2 Unknown
NCT05170256 2022-08-12
HERES
Rigshospitalet, Denmark
Phase 2 Unknown
NCT05469061 2022-07-21
Tislelizumab in Combination With Chemotherapy for Conversion Therapy of Locally Nonresectable ESCC
The First Affiliated Hospital with Nanjing Medical University
Phase 2 Unknown
NCT04215471 2022-06-14
NATION1907II
Shanghai Zhongshan Hospital
Phase 2 Unknown
NCT05322499 2022-04-11
Phase II Clinical Study of Camrelizumab Combined With Chemotherapy or Anlotinib in Advanced Esophageal Squamous Cell Cancer
Zhejiang Cancer Hospital
Phase 2 Unknown
NCT04390958 2022-03-15
Neoadjuvant Chemotherapy With Nab-paclitaxel Plus Cisplatin and Capecitabine for Locally Advanced Thoracic Esophageal Squamous Cell Carcinoma
ChineseAMS
Phase 2 Unknown
NCT05265962 2022-03-04
Decitabine Plus Penpulimab as Second-line Therapy for Advanced ESCC Treated With PD-1 Blockade
The First Affiliated Hospital of Zhengzhou University
Phase 2 Unknown
NCT04177797 2022-02-09
Toripalimab With Neoadjuvant Chemotherapy for Locally Advanced Esophageal Squamous Cell Carcinoma
Sichuan Cancer Hospital and Research Institute
Phase 2 Unknown
NCT05174325 2021-12-30
Effectiveness of Neoadjuvant Chemotherapy Combined With PD-1 Monoclonal Antibody in the Treatment of Operable Esophageal Squamous Cell Carcinoma
The First Affiliated Hospital of Soochow University
Phase 2 Unknown
NCT05007145 2021-12-21
REVO
Fujian Cancer Hospital
Phase 2 Unknown
NCT05044728 2021-09-16
Exploration of Immunodynamic Monitoring in the Population Evaluation of Neoadjuvant Chemotherapy Immunotherapy in Patients With Solid Tumors of the Chest.
Sichuan Cancer Hospital and Research Institute
Phase 2 Unknown
NCT03800953 2021-09-08
The Ave-CRT Study for Newly Diagnosed Metastatic Esophageal Squamous Cell Carcinoma
National Taiwan University Hospital
Phase 2 Unknown
NCT03387904 2021-09-02
Study of Anlotinib Plus Irinotecan in Patients With Esophageal Squamous Cell Carcinoma
The First Affiliated Hospital of Zhengzhou University
Phase 2 Unknown
NCT04514835 2021-08-25
A Phase â…¡ Trials of Sintilimab as Consolidation Therapy After Radical Concurrent Chemoradiotherapy in Locally Advanced Unresectable ESCC
The First Affiliated Hospital of Zhengzhou University
Phase 2 Unknown
NCT04063683 2021-08-24
Paclitaxel and DDP Combined With Anlotinib in the First-line Treatment for Patients With Advanced Esophageal Squamous Cell Carcinoma（ESCC）.
Henan Cancer Hospital
Phase 2 Unknown
NCT04984018 2021-07-30
Chidamide Plus Camrelizumab as Second-line Therapy for Advanced ESCC Treated With PD-1 Blockade
The First Affiliated Hospital of Zhengzhou University
Phase 2 Unknown
NCT04880811 2021-07-13
Afatinib Plus Toripalimab in Previously Treated ESCC With EGFR Overexpression or EGFR Amplification
Peking University
Phase 2 Unknown
NCT03766178 2021-07-07
Study of Anti-PD-1 Antibody SHR-1210 Plus Nimotuzumab in the Treatment of Advanced Esophageal Squamous Cell Carcinoma
The First Affiliated Hospital of Zhengzhou University
Phase 2 Unknown
NCT04275986 2021-07-07
Concurrent Chemoradiotherapy After Endoscopic Resection for Stage I Esophageal Carcinoma
ChineseAMS
Phase 2 Unknown
NCT04866381 2021-04-29
An Exploratory Clinical Study of SHR6390 and SHR1020 in the Treatment of Esophageal Squamous Cell Carcinoma After Progression on PD-1 Antibody
Tianjin Medical University Cancer Institute and Hospital
Phase 2 Unknown
NCT03585530 2021-04-06
Raltitrexed Concurrent With Radiotherapy for Elderly Chinese Patients With Squamous Cell Carcinoma of Esophagus
Huai'an First People's Hospital
Phase 2 Unknown
NCT03791905 2021-03-23
PET Imaging-guided Chemoradiotherapy in Esophageal Squamous Cell Carcinoma
Sun Yat-sen University
Phase 2 Unknown
NCT04767295 2021-02-23
A Study of Camrelizumab Combined With Chemotherapy as Neoadjuvant Therapy in Adcanced Esophageal Squamous Cell Carcinoma (ESCC)
Hunan Cancer Hospital
Phase 2 Unknown
NCT03377400 2020-12-17
Definitive CCRT Combined With Durvalumab and Tremelimumab for Inoperable Esophageal Cancer
Samsung Medical Center
Phase 2 Unknown
NCT04644250 2020-11-25
Combination of Toripalimab and Neoadjuvant Chemoradiotherapy for Locally Advanced Esophageal Squamous Cell Carcinoma
The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
Phase 2 Unknown
NCT04602013 2020-10-26
Sintilimab Injection Combined With Concurrent CCRT in Locally Advanced Esophageal Squamous Cell Carcinoma
Sichuan Cancer Hospital and Research Institute
Phase 2 Unknown
NCT04481100 2020-10-14
CCRT With Itraconazole in Locally Advanced Squamous Esophageal Cancer
Hangzhou Cancer Hospital
Phase 2 Unknown
NCT04503967 2020-08-07
OASIS
Shanghai Zhongshan Hospital
Phase 2 Unknown
NCT02123381 2020-03-17
Changes in Tumor Tissue and Serum Biomarkers Before and After Cetuximab Combined With Preoperative Radiotherapy in Locally Advanced Thoracic Esophageal Squamous Cell Carcinoma
Sichuan Cancer Hospital and Research Institute
Phase 2 Unknown
NCT03603756 2020-02-11
SHR-1210 in Combination With Apatinib and Chemotherapy in Patients With Advanced Esophageal Squamous Cell Cancer
ChineseAMS
Phase 2 Unknown
NCT03913182 2020-02-05
Apatinib in the Treatment of Recurrence or Metastasis of Esophageal Cancer
Shanghai Chest Hospital
Phase 2 Unknown
NCT04229849 2020-01-18
Anrotenib Plus Toripalimab Versus Toripalimab in Patients With Advanced Esophageal Squamous Cell Carcinoma
Henan Cancer Hospital
Phase 2 Unknown
NCT04006041 2019-12-26
Combination of Toripalimab and Neoadjuvant Chemoradiotherapy in Esophageal Cancer
Sun Yat-sen University
Phase 2 Unknown
NCT04115618 2019-10-04
SIB in Upper Thoracic Esophageal Squamous Cell Carcinoma
Fudan University
Phase 2 Unknown
NCT04054518 2019-08-13
DESC
Instituto do Cancer do Estado de São Paulo
Phase 2 Unknown
NCT03185988 2019-07-19
Anti-HER2 Therapy in Patients of HER2 Positive Metastatic Carcinoma of Digestive System
Peking University
Phase 2 Unknown